Wow, Anika's stock tanked post-Q1 2025 earnings due to a 10% revenue drop, lower OEM pricing, manufacturing issues, and reduced guidance.
Anika Therapeutics' stock tanked after the Q1 2025 earnings call due to several negative financial and operational updates:
Revenue Decline: Total revenue fell 10% year-over-year to $26.2 million, driven by a 23% drop in the OEM channel, primarily due to lower pricing for Monovisc and Orthovisc sold by J&J MedTech.
Gross Margin Drop: Gross margin decreased to 56% from 65% in Q1 2024, impacted by lower high-margin J&J sales and manufacturing yield issues with Monovisc and Cingal, caused by a raw material supplier change.
Lowered Guidance: Anika revised its 2025 OEM revenue guidance to a 16-20% decline (from a less severe expectation) and adjusted EBITDA guidance to -3% to +3% (down from 8-10%), reflecting persistent pricing pressure and manufacturing challenges.
Manufacturing Issues: Lower production yields for Monovisc and Cingal, expected to continue into Q2, further pressured margins and profitability.
Despite strong commercial channel growth (up 18%) and progress with Integrity, these negative factors—particularly the significant OE...
